Rare cancers are not so rare: The rare cancer burden in Europe

Gatta, Gemma; Zwan, Jan Maarten van der; Casali, Paolo G.; Siesling, Sabine; Tos, Angelo Paolo Dei; Kunkler, Ian; Otter, Renée; Licitra, Lisa; Mallone, Sandra; Tavilla, Andrea; Trama, Annalisa; Capocaccia, Riccardo

doi:10.1016/j.ejca.2011.08.008

Cited by 592 publications

(496 citation statements)

References 10 publications

Supporting

Mentioning

472

Contrasting

Unclassified

Order By: Relevance

“…NETs of the lung will not be described in this article as their European incidence rate was 7.3 per 100.000 person-years, and therefore not considered to be rare. 18 …”

Section: Tumour Groupingmentioning

confidence: 99%

Rare neuroendocrine tumours: Results of the surveillance of rare cancers in Europe project

Zwan

Trama

Otter

et al. 2013

European Journal of Cancer

Self Cite

View full text Add to dashboard Cite

“…NETs of the lung will not be described in this article as their European incidence rate was 7.3 per 100.000 person-years, and therefore not considered to be rare. 18 …”

Section: Tumour Groupingmentioning

confidence: 99%

Rare neuroendocrine tumours: Results of the surveillance of rare cancers in Europe project

Zwan

Trama

Otter

et al. 2013

European Journal of Cancer

Self Cite

View full text Add to dashboard Cite

“…According to RARECARE estimates -based on cancer registry data -there were 3566 persons per 100,000 with a diagnosis of any type of cancer in the European Union on 1st January 2003, equivalent to a total prevalence of nearly 17.8 million. 2 The number of prevalent cancer cases is projected to increase as the European population continues to age, as cancer incidence increases, and as survival improves. 3 EUROCARE estimated that the proportion of patients (diagnosed from 1988 to 1999) considered cured of their cancer (all cancers combined) varied between 38% and 59% in women, and 21% and 47% in men, by country.…”

Section: Introductionmentioning

confidence: 99%

Cancer rehabilitation indicators for Europe

Baili

Hoekstra-Weebers²,

Hoof

et al. 2013

European Journal of Cancer

View full text Add to dashboard Cite

Little is known of cancer rehabilitation needs in Europe. EUROCHIP-3 organised a group of experts to propose a list of population-based indicators used for describing cancer rehabilitation across Europe. The aim of this study is to present and discuss these indicators. A EUROCHIP-3 expert panel reached agreement on two types of indicators. (a) Cancer prevalence indicators. These were proposed as a means of characterising the burden of cancer rehabilitation needs by time from diagnosis and patient health status. These indicators can be estimated from cancer registry data or by collecting data on follow-up and treatments for samples of cases archived in cancer registries. (b) Indicators of rehabilitation success. These include: return to work, quality of life, and satisfaction of specific rehabilitation needs. Studies can be performed to estimate these indicators in individual countries, but to obtain comparable data across European countries it will be necessary to administer a questionnaire to randomly selected samples of patients from population-based cancer registry databases. However, three factors complicate questionnaire studies: patients may not be aware that they have cancer; incomplete participation in surveys could lead to bias; and national confidentiality laws in some cases prohibit cancer registries from approaching patients. Although these studies are expensive and difficult to perform, but as the number of cancer survivors increases, it is important to document their needs in order to provide information on cancer control.

show abstract

“…[1] Foarte rar au fost descrise și GIST-uri extragastrointestinale [2]. Incidența a fost estimata la 1.5/100000 pe an [3].…”

Section: Discuțiiunclassified

Bolnav cu Gist Gastric Gigant; Supraviețuire Nesperată Prezentare de Caz

2014

J de Chirurgie

View full text Add to dashboard Cite

Background: Gastrointestinal Stromal Tumors (GIST) are rare neoplasms, with sever prognosis in advanced cases. Until the discovery of Tyrosin Kinase Inhibitors (TKI), the life expectancy was very poor for patient with metastatic tumors, postoperative relapses or unresectable disease. Introduction of TKI therapy provided an unexpected survival rate, controlling the disease with very good tolerance.

show abstract

Rare cancers are not so rare: The rare cancer burden in Europe

Cited by 592 publications

References 10 publications

Rare neuroendocrine tumours: Results of the surveillance of rare cancers in Europe project

Rare neuroendocrine tumours: Results of the surveillance of rare cancers in Europe project

Cancer rehabilitation indicators for Europe

Bolnav cu Gist Gastric Gigant; Supraviețuire Nesperată Prezentare de Caz

Contact Info

Product

Resources

About